Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 +2.06%78 Cash Ratio is 0.10 as of Jun. 2026, which is 91% below its 10-year median of 1.15. GuruFocus rates TPE:4119 with a GF Score™ of 78/100 and a GF Value™ of NT$74.47 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 965 Drug Manufacturers companies, Sci Pharmtech ranks worse than 84.97% on this metric.
Sci Pharmtech has a Cash Ratio of 0.10. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Sci Pharmtech's Cash Ratio or its related term are showing as below:
TPE:4119'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 1.15 Max: 2.39
Current: 0.1
During the past 13 years, Sci Pharmtech's highest Cash Ratio was 2.39. The lowest was 0.05. And the median was 1.15.
TPE:4119's Cash Ratio is ranked worse than 84.97% of 965
companies
in the Drug Manufacturers industry
Industry Median: 0.58
vs TPE:4119: 0.10
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Sci Pharmtech Cash Ratio Related Terms
Sci Pharmtech Cash Ratio Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a Cash Ratio of 0.10 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sci Pharmtech and its competitors. This is 91% below median its historical median of 1.15. Over the past decade, Sci Pharmtech's Cash Ratio has ranged from 0.05 to 2.39. According to the industry distribution chart, Sci Pharmtech ranks #820 out of 965 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Sci Pharmtech's Cash Ratio too high?
Sci Pharmtech's current Cash Ratio of 0.10 is 91% below median its 10-year median of 1.15. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 2.39. The Drug Manufacturers industry median Cash Ratio is 0.58. Sci Pharmtech's value of 0.10 is 82.8% below this industry median. Based on the distribution chart, Sci Pharmtech ranks #820 out of 965 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sci Pharmtech has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #820 out of 965 companies for Cash Ratio. This places Sci Pharmtech in the lower half of its industry. The industry median Cash Ratio is 0.58. Sci Pharmtech's value of 0.10 is 82.8% below this benchmark. Historically, Sci Pharmtech's own Cash Ratio has ranged from 0.05 to 2.39 over the past decade. While the company's 10-year median is 1.15 vs. the industry median of 0.58, Sci Pharmtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.58, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current Cash Ratio of 0.10 is 82.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current Cash Ratio is 0.10, which is 91% below median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$74.47, compared to a current price of NT$54.40 — trading 27% below its estimated fair value. The current Cash Ratio is 0.10, which is 91% below median its 10-year median of 1.15 and 82.8% below the Drug Manufacturers industry median of 0.58. Sci Pharmtech's overall GF Score™ is 78/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Cash Ratio is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$54.40 is trading 27% below its estimated GF Value™ of NT$74.47.
GuruFocus considers Sci Pharmtech to be Modestly Undervalued.
Key valuation signals for TPE:4119:
Cash Ratio: 0.10 (91% below median its 10-year median of 1.15)
GF Value™: NT$74.47 vs. price of NT$54.40 (27% below fair value)
Industry Position: 82.8% below the Drug Manufacturers median (#820 of 965)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
78GF Score
Get the complete analysis for TPE:4119
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
